

January 23, 2025

VDP TO BEGIN MAILING “UNDER-TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTIONS” RETROSPECTIVE DUR INTERVENTION INFORMATION

BACKGROUND

VDP contracted with AbbVie to improve awareness, screening, diagnosis, and treatment of the Hepatitis C Virus (HCV). HCV is a liver infection caused by a virus and often develops into a long-term or chronic illness. If untreated, HCV can cause significant damage to the body, such as liver cancer and cirrhosis. VDP presented a retrospective drug utilization review intervention for the Under-Treatment of Chronic Hepatitis C Virus Infections at the Drug Utilization Review Board (DURB) meeting held on Oct. 25, 2024. The DUR Board approved the intervention.

KEY DETAILS

To improve awareness, screening, diagnosis, and treatment of HCV for Medicaid clients, VDP will conduct outreach and mail the intervention letters to identified fee-for-service and MCO providers on Jan. 24, 2025.

VDP requires no further action from the MCOs.

ADDITIONAL INFORMATION

MCOs may submit comments or questions regarding the intervention by email.